Long-term outcomes and prognostic factors of skull-base chondrosarcoma patients treated with pencil-beam scanning proton therapy at the Paul Scherrer Institute. 2016

Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland (D.C.W., S.B., R.M., F.A., A.B., A.J.L, R.S.); University of Bern, Bern, Switxerland (D.C.W.); University of Zürich, Zürich, Switzerland (D.C.W.); Department of Physics, ETH, Zürich, Switzerland (A.J.L.).

BACKGROUND Skull-base chondrosarcoma (ChSa) is a rare disease, and the prognostication of this disease entity is ill defined. METHODS We assessed the long-term local control (LC) results, overall survival (OS), and prognostic factors of skull-base ChSa patients treated with pencil beam scanning proton therapy (PBS PT). Seventy-seven (male, 35; 46%) patients with histologically confirmed ChSa were treated at the Paul Scherrer Institute. Median age was 38.9 years (range, 10.2-70.0y). Median delivered dose was 70.0 GyRBE (range, 64.0-76.0 GyRBE). LC, OS, and toxicity-free survival (TFS) rates were calculated using the Kaplan Meier method. RESULTS After a mean follow-up of 69.2 months (range, 4.6-190.8 mo), 6 local (7.8%) failures were observed, 2 of which were late failures. Five (6.5%) patients died. The actuarial 8-year LC and OS were 89.7% and 93.5%, respectively. Tumor volume > 25 cm(3) (P = .02), brainstem/optic apparatus compression at the time of PT (P = .04) and age >30 years (P = .08) were associated with lower rates of LC. High-grade (≥3) radiation-induced toxicity was observed in 6 (7.8%) patients. The 8-year high-grade TFS was 90.8%. A higher rate of high-grade toxicity was observed for older patients (P = .073), those with larger tumor volume (P = .069), and those treated with 5 weekly fractions (P = .069). CONCLUSIONS This is the largest PT series reporting the outcome of patients with low-grade ChSa of the skull base treated with PBS only. Our data indicate that protons are both safe and effective. Tumor volume, brainstem/optic apparatus compression, and age were prognosticators of local failures.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002813 Chondrosarcoma A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed) Chondrosarcomas
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
August 2020, Clinical oncology (Royal College of Radiologists (Great Britain)),
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
July 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
October 2016, Pediatric blood & cancer,
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
July 2013, International journal of radiation oncology, biology, physics,
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
October 2005, International journal of radiation oncology, biology, physics,
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
July 2012, International journal of radiation oncology, biology, physics,
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
December 2020, Pediatric blood & cancer,
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
November 2020, Radiation oncology (London, England),
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
May 2008, International journal of radiation oncology, biology, physics,
Damien C Weber, and Shahed Badiyan, and Robert Malyapa, and Francesca Albertini, and Alessandra Bolsi, and Antony J Lomax, and Ralf Schneider
January 1990, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Copied contents to your clipboard!